Refractory Acute Lymphoblastic Leukemia Recruiting Phase 1 Trials for Fludarabine (DB01073)

Also known as: Acute Lymphoblastic Leukemia, Refractory / Acute, refractory Lymphoblastic Leukemia / Acute, refractory Lymphocytic leukaemia / Acute, refractory Lymphocytic Leukemia / Acute lymphocytic leukemia refractory / Acute, refractory Lymphoblastic Leukaemia / Acute lymphocytic leukaemia refractory / Refractory Acute lymphoblastic leukaemia

IndicationStatusPhase
DBCOND0058624 (Refractory Acute Lymphoblastic Leukemia)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03241940Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell MalignanciesTreatment
NCT03326921HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantTreatment